Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

A drug from Amgen could give patients with a notoriously aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.  Full results from a late-stage...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。